Kalaris Therapeutics, Inc. Share Price
NASDAQ: KLRS | Micro CapKalaris Therapeutics, Inc. Stock Performance
Kalaris Therapeutics, Inc. Share Price Today
As of 29 October 2026, Kalaris Therapeutics, Inc.'s share price is $2.13. The stock opened at $2.10, compared to its previous close of $1.99. During today's trading session, Kalaris Therapeutics, Inc.'s share price traded between $2.10 and $2.10, with an average price of $2.10. Over the past 52 weeks, the stock has recorded a high of $11.81 and a low of $1.81. In terms of performance, Kalaris Therapeutics, Inc.'s share price has declined by 61.25% over the last six months and is down 56.07% on a year-on-year basis.
Kalaris Therapeutics, Inc. Share Price Chart
Kalaris Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Kalaris Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Kalaris Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Oct 2026 | $2.80 | $2.10 | -27.84% |
Sep 2026 | $3.91 | $2.91 | -30.30% |
Aug 2026 | $3.67 | $4.17 | +17.94% |
Jul 2026 | $4.43 | $3.54 | -15.61% |
Jun 2026 | $5.18 | $4.20 | -19.02% |
May 2026 | $5.50 | $5.18 | -5.99% |
Apr 2026 | $5.67 | $5.51 | -5.00% |
Mar 2026 | $10.45 | $5.80 | -43.85% |
Feb 2026 | $9.25 | $10.33 | +16.46% |
Jan 2026 | $8.12 | $8.87 | +5.34% |
Dec 2025 | $5.95 | $8.42 | +35.70% |
Nov 2025 | $4.81 | $6.21 | +27.67% |